IDiyas

For the Inventor, By the Inventor

Newark, DE, United States of America

Yigang He

USPTO Granted Patents = 14 

 

Average Co-Inventor Count = 3.4

ph-index = 3

Forward Citations = 19(Granted Patents)


Location History:

  • Wilmington, DE (US) (2022)
  • Newark, DE (US) (2021 - 2024)

Company Filing History:

goldMedal14 out of 15 
 
Nikang Therapeutics, Inc.
 patents

Years Active: 2021-2025

Loading Chart...
Loading Chart...
14 patents (USPTO):
1. 12435034 - Process of preparing 3-fluoro-5(((1R,2AR)-3,3,4,4-tetrafluoro-1,2A-dihydroxy-2,2A,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)-oxy)benzonitrile (2025-10-07),
2. 12415779 - Processes of making 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-benzonitrile and polymorphs thereof (2025-09-16),
3. 12391642 - Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors (2025-08-19),
4. 12264167 - Fused tricyclic ring derivatives as SRC homology-2 phosphate inhibitors (2025-04-01),
5. 12171741 - 2,3-dihydrobenzo[b]thiophene derivatives as hypoxia inducible factor-2(alpha) inhibitors (2024-12-24),
6. 12077506 - Indane derivatives as hypoxia inducible factor-2(α) inhibitors (2024-09-03),
7. 11753366 - Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors (2023-09-12),
8. 11634382 - Process of preparing 3-fluoro-5(((1R,2aR)-3,3,4,4-tetrafluoro-1,2a-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)-oxy)benzonitrile (2023-04-25),
9. 11518772 - Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors (2022-12-06),
10. 11459340 - Tri-substituted heteroaryl derivatives as Src homology-2 phosphatase inhibitors (2022-10-04),
11. 11420936 - Hypoxia inducible factor-2(alpha) inhibitors and their use in the treatment of diseases (2022-08-23),
12. 11267782 - Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2α inhibitors (2022-03-08),
13. 11034705 - Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors (2021-06-15),
14. 10894797 - Fused tricyclic ring derivatives as SRC homology-2 phosphatase inhibitors (2021-01-19),

Title: Yigang He: Innovator in Pharmaceutical Chemistry

Introduction

Yigang He is a prominent inventor based in Newark, DE (US), known for his significant contributions to pharmaceutical chemistry. With a total of 14 patents to his name, he has made remarkable strides in the field of drug synthesis and development.

Latest Patents

His latest patents include innovative processes for preparing complex chemical compounds. One notable patent details the process of preparing 3-fluoro-5-(((1R,2AR)-3,3,4,4-tetrafluoro-1,2A-dihydroxy-2,2A,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)-oxy)benzonitrile. This patent discloses methods for synthesizing intermediates that are essential for creating 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile or its pharmaceutically acceptable salts. Another patent focuses on processes for making 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-benzonitrile and its polymorphs. This disclosure also includes pharmaceutical compositions that comprise a crystalline polymorph form of the compound and methods for preparing such forms.

Career Highlights

Yigang He is currently associated with Nikang Therapeutics, Inc., where he continues to push the boundaries of pharmaceutical innovation. His work has been instrumental in developing new therapeutic agents that can potentially improve patient outcomes.

Collaborations

Throughout his career, Yigang has collaborated with notable colleagues, including Jiping Fu and Yan Lou, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Yigang He stands out as a key figure in pharmaceutical chemistry, with a strong portfolio of patents that reflect his dedication

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…